Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study
Cancer Medicine · 2024
DOI: 10.1002/cam4.70181 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2024. Verfasst von Ruopeng Su und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Everolimus, Angiomyolipoma, Kidney Neoplasms, Neoadjuvant Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Science and Technology Commission Research Project, the Incubating Program for Clinical Research and Innovation of Renji Hospital, Wu Jieping Medical Foundation.
Abstract (Originalsprache)
Objectives
To assess the efficacy and safety of preoperative neoadjuvant everolimus in renal angiomyolipomas (AML) patients with or without Tuberous Sclerosis Complex (TSC). Materials and Methods This multi‐institutional retrospective study enrolled renal AML patients who underwent partial nephrectomy (PN) or total nephrectomy after receiving at least 1 month of pre‐operative everolimus. Imaging evaluations were collected before and after treatment, along with demographic, surgical, and follow‐up information. The primary outcome was tumor volume reduction of ≥25%, with additional outcomes including recurrence, perioperative outcomes, renal function, and safety.
Results
From January 2015 to July 2022, 68 renal AML patients were studied—41 with TSC and 27 without. During everolimus treatment, 61.0% (25/41) of TSC patients and 44.4% (12/27) of non‐TSC patients achieved tumor reduction of ≥25%. Additionally, 41.5% (17/41) of TSC patients and 18.5% (5/27) of non‐TSC patients achieved a ≥ 50% reduction. Three TSC patients and 1 non‐TSC patient discontinued treatment due to side‐effects. Most patients (92.7% TSC, 85.2% non‐TSC) underwent PN. After everolimus treatment, the necessary total nephrectomy decreased to 41.2% (7/17) from baseline. Postoperatively, 1 grade 3 and 3 grade 2 complications occurred, with no grade 4 or 5 complications. After a median follow‐up of 24 months, only 1 TSC patient recurred with a diameter >3 cm. Retrospective nature is the major limitation of this study.
Conclusion
Everolimus was effective and well‐tolerated in neoadjuvant treatment for renal AML, especially in TSC patients. This neoadjuvant combination strategy of everolimus and PN could effectively controls recurrence and preserves renal function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Urology Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- Department of Urology, The Third Medical Centre, Chinese PLA General Hospital, Beijing, China.
- Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.
- Department of Urology, Xiangya Hospital, Central South University, Changsha, China.
- Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, National Urological Cancer Center, Beijing, China.
ORCID-Profile: Xiaoyi Hu, Guanghou Fu, Jitao Wu, Pei Dong, Jiwei Huang
Förderung
- Shanghai Science and Technology Commission Research Project
- the Incubating Program for Clinical Research and Innovation of Renji Hospital
- Wu Jieping Medical Foundation
- Basic Oncology Research Program from Bethune Charitable Foundation
Zitieren
APA
Su, R., Huang, T., Gu, L., Bao, Y., Liu, Z., Dao, P., Yao, L., Hu, X., Fu, G., Wu, J., Tricard, T., Wu, G., Chen, M., Li, C., Huang, Z., Zheng, B., Chen, Y., Xue, W., Guo, G., …, & Zhang, J. (2024). Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study. Cancer Medicine. https://doi.org/10.1002/cam4.70181
Vancouver
Su R, Huang T, Gu L, Bao Y, Liu Z, Dao P, et al. Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study. Cancer Medicine. 2024. doi:10.1002/cam4.70181
BibTeX
@article{Su2024,
author = {Su, Ruopeng and Huang, Tingxuan and Gu, Liangyou and Bao, Yige and Liu, Zhihong and Dao, Pinghong and Yao, Lin and Hu, Xiaoyi and Fu, Guanghou and Wu, Jitao and Tricard, Thibault and Wu, Guangyu and Chen, Minfeng and Li, Chancan and Huang, Zhiyang and Zheng, Bing and Chen, Yonghui and Xue, Wei and Guo, Gang and Dong, Pei and Huang, Jiwei and Zhang, Jin},
title = {Neoadjuvant everolimus in renal angiomyolipoma with or without tuberous sclerosis complex: Results from a multicenter, retrospective study},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70181}
}
EUVIMED